Spencer board OKs buyout

Spencer Pharmaceutical announced today that its board of directors is in favor of the buyout offer at $0.97 per share. The company has requested details from the acquirer as well as timeline and have requested that funds be transferred to an independent escrow agent. The company expects to release the name of the private equity fund on or before Nov. 19, and file appropriate supplemental information on the alternative reporting system of the OTC Markets. Spencer release

Suggested Articles

PureTech Health has decamped from Cambridge to Boston’s Seaport neighborhood as a step toward growing the company and ramping up its pipeline.

In this week's EuroBiotech Report, Sanofi cuts staff in R&D rejig, AstraZeneca bets on Korea and uniQure weighs buyout bids.

In our EuroBiotech roundup this week, BioNTech and Genmab start cancer trial, Oncopeptides posts cancer data and F-star hires CFO.